$NGNE News

Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Q1 EPS $(1.39) Misses $(1.36) Estimate

Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth

Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy

Neurogene To Highlight ICV As Routine Neurosurgical Procedure Providing Broad Biodistribution Of Gene Therapy To Brain And Nervous System At ASGCT Meeting

Neurogene To Highlight ICV As Routine Neurosurgical Procedure Providing Broad Biodistribution Of Gene Therapy To Brain And Nervous System At ASGCT Meeting

Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors

Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $180

Neurogene shares are trading higher. The company, on Tuesday, reported Q4 financial results.

Neurogene: Q4 Earnings Snapshot

Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates

Neurogene Q4 EPS $(1.13), Inline

Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference

Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Neurogene: Stock Soars On FDA Designation For Rett Gene Therapy - I'd Remain Cautious

Canaccord Genuity Initiates Coverage On Neurogene with Buy Rating, Announces Price Target of $200

12 Health Care Stocks Moving In Friday's Intraday Session

Neurogene Stock Soars On FDA Breakthrough Tag For Rett Gene Therapy